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Abstract. Baicalein (BL), a potential cancer chemopreventa-
tive flavone, has been reported to inhibit cancer cell growth 
by inducing apoptosis and causing cell cycle arrest in various 
human cancer cell models. Delivery of BL via nanolipo-
somes has been shown to improve its oral bioavailability and 
long‑circulating property in vivo. However, the role of BL in 
the inhibition of human chronic myeloid leukemia (CML) 
K562 cell growth and its underlying mechanisms has yet 
to be elucidated. In the present study, BL was formulated 
into liposomes with different sizes to improve its solubility 
and stability. The cytotoxic and pro‑apoptotic effects of 
free BL and liposomal BL were also evaluated. The results 
demonstrated that 100 nm liposomes were the most stable 
formulation when compared with 200 and 400 nm liposomes. 
Liposomal BL inhibited K562 cell growth as efficiently as free 
BL (prepared in DMSO), indicating that the liposome may be 
a potential vehicle to deliver BL for the treatment of CML. 
Flow cytometry analysis showed that there was significant 
(P<0.005) cell cycle arrest in the sub‑G1 phase (compared 
with vehicle control), indicating cell apoptosis following 
20 µM liposomal BL or free BL treatment of K562 cells for 
48 h. The induction of cell apoptosis by all BL preparations 
was further confirmed through the staining of treated cells 
with Annexin V‑fluorescein isothiocyanate/propidium iodide. 
A significant increase in reactive oxygen species (ROS) gene‑
ration was observed in free BL and liposomal BL treated cells, 
with a higher level of ROS produced from those treated with 
free BL. This indicated that cell apoptosis induced by BL may 
be via ROS generation and liposome delivery may further 
extend the effect through its long‑circulating property.
Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative 
disorder that is characterized by the unregulated growth of 
myeloid leukemia cells in the bone marrow and their accu-
mulation in the blood (1). Epidemiologic data suggest that 
CML incidence is one to two per 100,000 individuals, with 
15‑20% of adult leukemia cases being CML (2). While CML is 
commonly treated with tyrosine kinase inhibitors, an increase 
in drug resistance has been reported along with adverse side 
effects (3).
Baicalein (BL) is a bioactive flavone derived from the root 
of traditional Chinese medicine herb Scutellaria baicalensis 
Georgi, with broad antitumor activity against ovarian (4), 
prostate (5), breast (6), cervical (7) and lung (8) cancers. 
However, clinical application of free BL has been limited by its 
extensive first‑pass metabolism, low aqueous solubility, poor 
bioavailability, short half‑life (t1/2, 10 min) and its easy oxida-
tion (9-16). About 76% of the dose was found to be circulating 
as its conjugated metabolites even after intravenous adminis-
tration of BL in rats (10). Tian et al (17) demonstrated that 
the absolute bioavailability of BL ranges from 13.1 to 23.0% 
when it was administered via oral and intravenous routes in 
monkeys. Nanostructured lipid carriers such as liposomes 
have been developed to improve the stability and bioavail-
ability of BL (11).
Liposomes have been used recently as popular nanovesi-
cles for administration of oral drugs because they have good 
biocompatibility and biodegradability due to their similarity 
in structure to the cell‑surface phospholipid bilayer. They 
have also been shown to display excellent drug loading rates, 
as well as targeting and slow releasing actions, enhanced 
oral bioavailability and long‑circulating properties (18-25). 
Despite these advantages, there are no studies in the literature 
describing the use of liposomes to deliver BL to K562 cells or 
to investigate the antitumor activities of free BL and liposomal 
BL on these cells.
Previous investigations have shown that BL has multiple 
biological activities, including anti‑inflammatory (26) anti-micro-
bial (27) and antioxidant (28) properties. BL exerts an antitumor 
effect by promoting the apoptosis or inhibiting the proliferation 
of cancer cells (29-32) through multiple signalling pathways 
including the cell proliferation pathway, the cell apoptosis and 
caspase activation pathway, the tumor suppressor pathway and the 
protein kinase pathway (33,34). However, the exact mechanism of 
Liposome‑delivered baicalein induction of myeloid leukemia 
K562 cell death via reactive oxygen species generation
SCARLET XIAOYAN WANG,  XUESONG WEN,  CELIA BELL  and  SANDRA APPIAH
Department of Natural Sciences, Faculty of Science and Technology, Middlesex University, London NW4 4BT, UK
Received September 11, 2017;  Accepted December 18, 2017
DOI: 10.3892/mmr.2018.8396
Correspondence to: Dr Scarlet Xiaoyan Wang or Dr Sandra Appiah, 
Department of Natural Sciences, Faculty of Science and Technology, 




Key words: baicalein, liposomes, chronic myeloid leukemia, cell 
cycle, apoptosis, reactive oxygen species
WANG et al:  LIPOSOME‑DELIVERED BAICALEIN INDUCES MYELOID LEUKEMIA K562 CELL DEATH 4525
apoptosis and its related pathways induced by BL is not yet fully 
understood.
In the present study, we evaluated different sizes of 
liposome formulations for the delivery of BL. We further inve‑
stigated the cytotoxicity and pro‑apoptotic effects of BL and 
liposomal BL on CML K562 cells. The mechanism involved 
in this process was also explored.
Materials and methods
Materials. Soy phosphatidylcholine (PC) was purchased 
from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). Meth 
oxypolyethyleneglycol‑di‑stearoyl‑phosphatidylethanolamine 
(DSPE‑PEG2000, with mPEG MW2000 Da) was obtained 
from Genzyme (Oxford, UK). Cholesterol (Chol), PBS, 
dialysis tubing, propidium iodide (PI), RNase and BL were 
all purchased from Sigma‑Aldrich (UK). Methanol, dichlo-
romethane, CyQUANT® Cell Proliferation Assay kit and 
Annexin V‑FITC/PI Apoptosis Detection kit were both from 
Thermo Fisher Scientific (Loughborough, UK). RPMI-1640, 
L‑glutamine, penicillin‑streptomycin and fetal bovine serum 
(FBS) were all from Invitrogen Life Technologies (UK). The 
CellTiter 96® AQueous One Solution Cell Proliferation Assay 
(MTS) kit was purchased from Promega (Southampton, UK).
Liposome preparation and characterization. Three types of 
liposomes with different diameters were prepared. Liposomes 
were composed of soy PC, cholesterol, and methoxypolyeth-
yleneglycol‑di‑stearoyl‑phosphatidylethanolamine (DSPE‑ 
PEG2000; Genzyme). Liposomes were prepared as 
described elsewhere (35). Briefly, the lipids were dissolved 
in methanol:dichloromethane 1:2 (v/v) at a PC:Chole-
sterol:DSPE‑PEG2000 molar ratio of 78.9:19.7:1.4 at room 
temperature. BL was dissolved in the solvent with lipid 
mixture when formulating the liposomes. Different lipid/BL 
mass ratios were tested before settling on a fixed ratio of 10:1. 
The lipid mixtures were deposited on the side wall of the 
rotary glass vial by removing the solvent with nitrogen. The 
dried lipid films were hydrated in 10 mM sodium phosphate 
buffer pH 7.4. This process led to the spontaneous formation 
of pegylated liposomes. The liposomes were then down‑sized 
by passing through 0.1, 0.2 or 0.4 µm polycarbonate membrane 
syringe filters (Whatman®; Whatman, Inc., Clifton, NJ, USA) 
to produce lipo1, 2 and 3 suspensions, respectively. Free BL 
was removed by dialysis (14,000 Da cutoff membrane) against 
10 mM sodium phosphate buffer pH 7.4 overnight. The size 
and ζ‑potential of liposomes were measured by dynamic light 
scattering on a Zetasizer‑Nano ZS (Malvern Instruments Ltd., 
Malvern, UK).
Cell culture. Human leukemia K562 cells were purchased 
from ATCC (UK). Cells were cultured in RPMI‑1640 media 
containing 10% fetal calf serum, 100 U/ml of penicillin, 
100 mg/ml streptomycin in 75 cm2 flasks. The cells were 
grown in a humidified incubator containing 5% CO2 and 95% 
air at 37˚C. Cells growing in the log phase and free from 
mycoplasma was used in this study.
Cytotoxicity assay. K562 cells were cultured at a density of 
6x104 cells/well in 96‑well plates overnight and treated with 
different concentrations of BL and control liposomes for 
48 h. 3‑(4,5‑dimethylthiazol‑2‑yl)‑5‑(3‑carboxymethoxyphe
nyl)‑2‑(4‑sulfophenyl)‑2H‑tetrazolium (MTS) solution (50 µl) 
from CellTiter 96® AQueous One Solution Cell Proliferation 
Assay kit was added to detect live cells in each well as per 
manufacturer's instructions. Cells were incubated for 30 min 
at 37˚C with 95% air and 5% CO2. The absorbance of the 
solution was measured at 490 nm by FLUOstar Omega (BMG 
Labtech, Aylesbury, UK). Each treatment was conducted in 
triplicates. The cell viability was expressed as a percentage 
of cell viability of liposome treated cells relative to untreated 
controls.
Cell proliferation assay. Cell proliferation assays were 
conducted with the CyQUANT® Direct Cell Proliferation 
Assay Kit (Thermo Fisher Scientific) to avoid interference 
from the color of BL. K562 cells were cultured at a density 
of 5,000 cells/well in 96‑well plates overnight and treated 
with different concentrations of free BL or liposomal BL 
(0.185‑100 µM) for 48 h. CyQUANT® Detection reagent 
(100 µl) was added to detect live cells in each well as per 
manufacturer's instructions. Cells were incubated for 60 min 
at 37˚C with 95% air and 5% CO2. The fluorescence of the 
solution was recorded at 485 (ex)/520 (em) nm by FLUOstar 
Omega (BMG Labtech). Cell viability was expressed as a 
percentage of cell survival of treated cells relative to untreated 
controls.
Cell cycle and cell apoptosis analysis. Approximately 
1x105 K562 cells/well in 96‑well plates were incubated with 
20 µM free BL or liposomal BL for 48 h. The cells were 
centrifuged, resuspended in binding buffer and treated with 
Annexin V‑FITC and PI for 5 min before analysis for cell apop-
tosis. For cell cycle analysis, the cells were harvested, washed 
and fixed gently (drop by drop) in 70% ethanol and kept at 4˚C 
for 30 min. The cells were then resuspended in PBS containing 
40 µg/ml PI and 0.1 mg/ml RNase for cell cycle analysis. After 
30 min incubation at 37˚C in the dark, 10,000 cells/sample 
were analyzed were analysed for DNA content by flow cytom-
etry on BD FACSCalibur (BD Biosciences, Oxford, UK) and 
the cell cycle distribution was determined using a CellQuest 
software (Becton‑Dickinson, Franklin Lakes, NJ, USA). The 
percentage of cell population that had undergone apoptosis 
and those in different phases of the cell cycle were assessed 
accordingly.
Intracellular reactive oxygen species (ROS) assay. The 
measurement of intracellular ROS was determined by the 
Cellular Reactive Oxygen Species Detection Assay kit (Abcam, 
Cambridge, UK), which uses the cell permeant reagent 
2',7'‑dichlorofluorescin diacetate (DCFDA), a fluorogenic dye 
that measures ROS activity within the cell. Briefly, K562 cells 
were cultured in complete phenol‑red free RPMI medium at a 
density of 1.5x105 cells/well in 96‑well plates and were treated 
with 20 µM BL or liposomal BL for 48 h. After the incubation 
time, the cell treatments were overlaid with 20 µM DCFDA 
(100 µl) and incubated at 37˚C for further 30 min in the dark. 
The fluorescence of the treatments was detected at the excita-
tion and emission spectra of 485 and 520 nm, respectively, by 
FLUOstar Omega (BMG Labtech).
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Statistical analysis. Results were presented as mean ± standard 
deviation (SD). Statistical significance was tested by paired 
t‑test or one‑way ANOVA analysis. Differences between 
experimental groups were considered significant when the 
P‑value <0.05.
Results
Liposome preparation and characterization. Three groups 
of liposome suspensions: lipo1 (100 nm), lipo2 (200 nm) and 
lipo3 (400 nm), were prepared to investigate whether the size 
of the liposomes contributed to the efficiency of BL encapsula-
tion. BL/PC 1:10 (w/w) was dissolved in the solvent with lipid 
mixture when formulating the liposomes. Unincorporated 
BL was removed by dialysis and the concentration of BL in 
the liposome was determined by dissolving the liposomes in 
methanol. The absorbance of BL was recorded at 278 nm by 
FLUOstar Omega (BMG Labtech). Phospholipid (PC) was 
detected in the liposomes by the Stewart assay (36). Drug 
encapsulation efficiency was determined by encapsulated BL 
divided by original BL corrected by PC concentration. The 
final liposome samples were characterized and the data was 
shown in Table I, with the drug encapsulation efficiency from 
high to low: Lipo2 > lipo1 > lipo3.
The size and zeta potential of liposomes were deter-
mined by dynamic light scattering (Fig. 1A). Three groups 
of control liposomes displayed average diameters of 125, 161 
and 230 nm, respectively, with polydispersity of 0.1 for lipo1 
and lipo2, 0.2 for lipo3. The average diameters for lipo2 and 
lipo3 were below 200 and 400 nm, which may be due to the 
quality control of the filters (37). The negative ζ‑potential of the 
liposomes was attributed to one of the liposome components 
DSPE‑PEG2000 which is negatively charged. The stability of 
liposomes was investigated by comparing the size and zeta 
potential changes over a one month storage period at 4˚C in 
10 mM phosphate buffer pH 7.4 (Fig. 1B). The results showed 
Table I. Characterisation of the liposomes.
 Baicalein PC Drug
Sample (mM) (mg/ml) encapsulation (%)
Control lipo1 ‑ 18.6±1.2 ‑
(100 nm)
Lipo1‑BL 2.3±0.1 22.6±0.1 28
Control lipo2 ‑ 20.3±0.9 ‑
(200 nm)
Lipo2‑BL 2.5±0.2 20.7±0.9 32
Control lipo3 ‑ 18.0±1.3 ‑
(400 nm)
Lipo3‑BL 2.0±0.3 20.2±0.4 26
Data are presented as the mean ± standard deviation of three replicate 
measurements. lipo1, 100 nm liposome; lipo2, 200 nm liposome; 
lipo3, 400 nm liposome; BL, baicalein; PC, phosphatidycholine.
Figure 1. Determination of liposome sizes and stability over a 1 month period. (A) Characterization of the three groups of liposomes with different sizes. 
(B) Diameter and ζ‑potential of the liposome formulations over a 1 month period. Data are shown as the mean ± standard deviation of three replicate 
measurements in one representative experiment of at least two independent experiments. Using a paired t‑test, significant changes in diameter were observed 
for lipo3 control and lipo3‑BL following 1 month storage at 4˚C. Significant differences in ζ‑potential were observed for lipo2 control, lipo3 control and 
lipo2‑BL following 1 month storage at 4˚C. *P<0.05 and **P<0.005 vs. 0 months. Lipo1, 100 nm liposome; lipo2, 200 nm liposome; lipo3, 400 nm liposome; 
BL, baicalein; CT, control.
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that lipo1 formulation was the most stable, with no statistically 
significant changes in diameter or ζ‑potential over at least a 
one month period.
In vitro cytotoxicity of the liposomes. Potential cytotox-
icity of the liposomes was measured from cell viability 
relative to control K562 cells treated with medium only. 
MTS assay demonstrated that cell viability was between 
80 and 120% in relation to the control samples (Fig. 2). 
Statistical analysis showed no evidence of liposome toxicity 
at phosphatidylcholine concentrations up to 1.6 mg/ml.
Liposomal BL inhibits proliferation of K562 cells. The 
CyQUANT® Direct Cell Proliferation Assay kit was used to 
evaluate the cytotoxicity of liposomal BL. The cell prolifera-
tion assay was assessed after cells were treated for 48 h with 
the encapsulated drug. Exposure to free and liposomal BL 
inhibited leukemia cell line K562 growth in a concentra-
tion‑dependent manner (Fig. 3). The results showed that there 
was no significance difference between the antiproliferative 
effects of liposomal BL and those of free BL at equimolar 
concentrations. No inhibition effects were observed from 
three groups of control liposomes, which was consistent with 
the MTS assay showing no cytotoxicity from the control lipo-
somes.
Effect of BL on cell cycle progression and cell death. 
K562 cells were exposed to three different sizes of control 
liposomes and their relevant liposomal encapsulated BL for 
48 h. Staining procedures using PI or Annexin V‑FITC/PI 
were conducted to evaluate the effect of BL preparations on 
cell cycle and cell death, respectively, using a flow cytom-
eter. Cells in each sample from different phases (sub‑G1, 
G1, S and G2/M) were presented and their percentage in 
each phase was calculated and shown in Table II; viable 
and non‑viable (necrotic, early apoptotic and late apoptotic) 
cells were calculated and shown in Table III. All the BL 
preparations showed significant increase (P<0.005) in their 
populations in the sub‑G1 phase and significant decrease 
(P<0.01) in cell viability in comparison of their relative 
control sample.
Intracellular ROS production. The cell permeant reagent 
DCFDA, a fluorogenic dye that measures ROS activity 
within cells, was used to investigate whether intracellular 
ROS production was involved in the mechanism of apoptosis 
caused by BL. Analysis indicated that all BL preparations 
induced significant ROS generation (as determined by the 
fluorescence changes normalized as percentage increase over 
the untreated cells control level). About 20‑30% increase 
(P<0.05) of ROS production was observed when K562 cells 
were treated with liposome encapsulated BL, and 50% 
increase (P<0.001) following treatment with non‑encapsu-
lated BL or free BL (Fig. 4). Moreover, there was a significant 
difference in ROS induction between the treatments with 
liposomal BL and free BL (Fig. 4).
Figure 2. Cell viability of K562 cells following 48 h incubation with control 
liposomes. No significant difference in cell viability was observed against 
medium only treatment from one‑way analysis of variance (P>0.05). Data 
are shown as the mean ± standard deviation of three replicate measurements 
in one representative experiment of at least two independent experiments. 
Lipo1, 100 nm liposome; lipo2, 200 nm liposome; lipo3, 400 nm liposome; 
PC, phosphatidylcholine; CT, control.
Figure 3. Effects of free BL and liposomal BL on cell proliferation as assessed 
by CyQUANT® assay. Liposomal BL demonstrated equivalent inhibitory 
effects on the growth of K562 cells when compared with free BL. No inhibi-
tory effects were observed from the three groups of control liposomes from 
one‑way analysis of variance (P>0.05). Values represent the mean ± standard 
deviation of three replicate measurements in one representative experiment 
of three independent experiments. Lipo1, 100 nm liposome; lipo2, 200 nm 
liposome; lipo3, 400 nm liposome; BL, baicalein.
Figure 4. Effects of free BL and liposomal BL on intracellular ROS 
generation. K562 cells were stained with 20 µM DCFDA following 24 h 
treatment with 20 µM BL. The results are presented as the percentage 
increase of ROS relative to control (untreated cells only). Data are expre‑
ssed as the mean ± standard deviation of three replicate measurements in 
one representative experiment of two independent experiments. *P<0.05, 
**P<0.005 and ***P<0.001 vs. control; #P<0.05 and ##P<0.005, as indicated. 
Lipo1, 100 nm liposome; lipo2, 200 nm liposome; lipo3, 400 nm liposome; 
BL, baicalein; DCFDA, 2',7'‑dichlorofluorescin diacetate; ROS, reactive 
oxygen species.
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Discussion
BL is a potent antitumor agent, but its poor solubility in aqueous 
solution, instability and relative toxicity affect its bioavail-
ability and application in humans. In this study, we prepared 
three groups of liposomal BL with different sizes to enhance 
its solubility and stability and investigated their ability to affect 
proliferation of CML K562 cells in vitro. Earlier research has 
shown that uncoated liposomes were quickly cleared from the 
blood by the reticuloendothelial system (38). Therefore, lipo-
somes coated with polyethylene glycol (PEG), shown to increase 
oral bioavailability of BL in vivo (11), were employed in this 
study.
A previous study has demonstrated that internalization 
of liposomes by murine macrophages was similar with lipo-
some size of between 100 and 200 nm, but was 1.7 times 
higher with liposomes larger than 400 nm, indicating that the 
degree of internalization is positively related to the size of 
the liposome (39). These researchers also suggested that PEG 
coating significantly reduced endocytosis of liposomes (39). 
However, others have reported that immunoliposomes of 
~100 nm in size may be ideal for intraperitoneal and intra-
venous (i.p./i.v.) administration in order to achieve high 
plasma concentration and subsequent tumor targeting using 
tumor vasculature, whereas immunoliposomes of a larger 
size (>300‑400 nm) may be preferable for i.p. administration 
and retention of the liposomes in the peritoneal cavity for 
targeting tumors located in this site and surrounding areas (40).
In this study, three groups of liposome formulations with 
diameters of 100, 200 or 400 nm were evaluated for their 
stability, drug encapsulation efficiency, cytotoxicity, and 
pro‑apoptotic effects on K562 cells. The results showed that 
the 100 nm liposome formulation was the most stable, with no 
significant changes in diameter or zeta potential over at least a 
one month period. The 200 nm liposome showed the highest 
drug encapsulation efficiency. Liposomal BL displayed similar 
Table III. Percentage of cell populations of viable and non‑viable cells exhibiting structural properties of different cell death types 
following exposure to 20 µM BL or liposomal baicalein for 48 h.
 Non‑viable cells
 ------------------------------------------------------------------------------------------------------------------------------------
Treatment group Viable cells Necrosis Late apoptosis/secondary necrosis Early apoptosis
Untreated cells 84.3±8.0 1.4±0.5 9.5±5.8 4.9±1.6
Control lipo1 (100 nm) 84.5±3.7 1.1±0.1 8.8±3.7 5.6±0.1
Lipo1‑BL 65.8±3.9a 4.6±1.0 17.3±1.0 12.3±3.8
Control lipo2 (200 nm) 85.8±0.1 3.7±3.8 6.7±1.1 3.9±2.9
Lipo2‑BL 65.1±2.2a 4.0±0.9 16.4±1.9 14.5±5.0
Control lipo3 (400 nm) 83.1±3.3 1.2±0.6 10.2±3.2 5.6±0.6
Lipo3‑BL 64.9±0.9a 4.4±0.7 16.3±2.7 14.5±4.3
DMSO 85.2±2.7 3.1±3.3 7.4±2.1 4.2±3.8
Free BL (in DMSO) 64.3±5.3a 2.9±0.5 15.5±4.1 17.3±1.7
The results are presented as the average percentage of the cell population (%) ± standard deviation. aP<0.01 vs. untreated cells. lipo1, 100 nm 
liposome; lipo2, 200 nm liposome; lipo3, 400 nm liposome; BL, baicalein.
Table II. Percentage of cell populations in different stages of the cell cycle following exposure to 20 µM BL or liposomal 
baicalein for 48 h.
Treatment group Sub‑G1 phase G1 phase S phase G2/M phase
Untreated cells 7.3±4.8 45.4±2.6 25.0±1.0 22.8±7.5
Control lipo1 (100 nm) 6.2±2.8 43.1±0.8 27.8±4.8 23.1±6.4
Lipo1‑BL 17.9±4.9a 41.7±1.5 21.6±3.4 19.4±2.7
Control lipo2 (200 nm) 4.8±1.3 46.3±3.0 25.0±0.9 23.4±5.6
Lipo2‑BL 19.9±3.3a 38.6±1.8 21.8±0.6 20.1±5.5
Control lipo3 (400 nm) 5.9±3.7 43.8±0.7 27.8±5.3 22.7±7.6
Lipo3‑BL 16.3±2.4a 39.9±2.1 25.0±1.3 20.0±0.7
DMSO 4.7±2.4 42.9±3.6 23.4±0.1 29.9±0.2
Free BL (in DMSO) 23.3±11.5a 36.5±8.1 25.9±1.9 15.3±5.4
The results are presented as the average percentage of the cell population (%) ± standard deviation. aP<0.005 vs. untreated cells. lipo1, 100 nm 
liposome; lipo2, 200 nm liposome; lipo3, 400 nm liposome; BL, baicalein.
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cell‑killing capabilities against the K562 cell line compared to 
free BL, indicating that liposomes could be a potential plat-
form for BL delivery to K562 leukemia cells due to increased 
solubility and stability.
Previous investigations have shown that BL exerts an 
antitumor effect by promoting apoptosis or inhibiting the 
proliferation of cancer cells (29-32) through multiple signalling 
pathways (33,34). For example, BL induces human osteosar-
coma cell line MG‑63 via ROS‑induced BNIPs expression (41) 
and it also induces G1 arrest in oral cancer cells by enhancing 
the degradation of cyclin D1 and activating AhR to decrease 
Rb phosphorylation. We suspected that the anti‑proliferative 
effect on K562 of BL is associated with ROS generation and 
cell cycle arrest. Therefore, in this study we investigated the 
molecular mechanisms by evaluating the generation of ROS 
and through cell cycle analysis. Significantly increased ROS 
production was observed when K562 cells were treated with 
both encapsulated and non‑encapsulated BL compared to 
untreated control cells (Fig. 4). However, the results revealed 
that there was no obvious cell cycle arrest observed after treat-
ment with free or liposomal BL (but showed an accumulation 
of apoptotic cell in the sub‑G1 phase) suggesting that BL 
induced K562 cell apoptosis is, in part, via ROS generation. 
Interestingly, more intracellular ROS was produced from cells 
treated with free BL compared with those treated with lipo-
somal BL, although no significant difference in cell apoptosis 
was observed. This suggests that other mechanisms may also 
be involved in BL induced K562 cell death.
ROS production occurs during normal metabolic functions 
such as respiration (42) and the detoxification of xenobiotics. 
ROS can cause cell death or lead to mutagenesis and increased 
cell proliferation depending of its relative amount compared 
to levels of endogenous antioxidants in the cells. Elevated 
ROS levels in cells can cause genetic mutations which 
can trigger programmed cell death via the mitochondrial 
(intrinsic) pathway of apoptosis (43), but may also result in 
normal cells becoming cancerous (42). Cancer cells increase 
their rate of ROS production compared with normal cells 
to hyperactivate the cell signalling pathways necessary for 
cellular transformation and tumorigenesis. Meanwhile, they 
increase the antioxidant capacity to maintain ROS homeo-
stasis and evade cell death (42,44,45). This altered redox 
environment of cancer cells may make them more susceptible 
to ROS‑manipulated therapies. It has been proposed that a 
disproportional increase in intracellular ROS can induce 
cancer cell cycle arrest, senescence and apoptosis. Apoptosis 
is linked to an increase in mitochondrial oxidative stress that 
causes cytochrome c release, an irrevocable event that leads 
to the activation of caspases and cell death (46,47). BL has 
been shown to trigger this apoptotic death program through 
ROS‑mediated mitochondrial dysfunction pathway in HL‑60 
cells (48). This was further confirmed by the other studies on 
human bladder cancer cells and osteosarcoma cell line (41,49). 
Our results indicated the same finding that BL induced cancer 
cell death by generation of ROS or/and possibly by depletion 
of cells from antioxidant proteins which protect cells from 
ROS‑mediated apoptosis. The difference in the ROS genera-
tion by free BL and liposomal BL suggests that other signalling 
pathways could be involved in the liposome‑BL induced cell 
death. Further studies in the future are required to identify 
other possible mechanisms of action of liposome‑delivered BL 
induction of myeloid leukemia cell death.
In this study, three groups of liposome formulations 
with diameters of 100, 200 and 400 nm were synthesized. 
The results demonstrated that the 100 nm liposome was 
the most stable formulation and that liposomal BL had an 
equivalent cytotoxic effect on K562 cells compared with 
free BL, indicating that liposomes may be a potential route 
for the delivery of BL with better solubility and stability. 
Enhanced intracellular ROS generation was induced by all BL 
preparations, but no significant cell cycle arrest was seen in 
any of the phases following liposomal BL or free BL treat-
ment, indicating that the mechanism involved in K562 cell 
apoptosis following BL treatment was at least in part via ROS 
generation. The findings are important as BL has been shown 
to be potent in killing several cancer cell lines. However, the 
hydrophobic nature of the drug hinders its application in vivo. 
The results from this study are promising in demonstrating 
the ability of liposome‑encapsulated BL to exert cytotoxicity 
on human chronic myeloid leukemic cells. However, further 
studies are required to determine if the liposomal formulation 
exerts selective cytotoxicity in leukemic cells compared to 
normal cells and to evaluate further possible mechanisms of 
action of the drug.
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